Atara Biotherapeutics, Inc.

NasdaqGS:ATRA Stock Report

Market Cap: US$50.0m

Atara Biotherapeutics Valuation

Is ATRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ATRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ATRA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ATRA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATRA?

Key metric: As ATRA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ATRA. This is calculated by dividing ATRA's market cap by their current revenue.
What is ATRA's PS Ratio?
PS Ratio0.2x
SalesUS$199.73m
Market CapUS$50.02m

Price to Sales Ratio vs Peers

How does ATRA's PS Ratio compare to its peers?

The above table shows the PS ratio for ATRA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average16.2x
PLUR Pluri
34.4x102.42%US$35.9m
MRSN Mersana Therapeutics
1.4x41.16%US$43.5m
CELU Celularity
0.9xn/aUS$55.6m
IGMS IGM Biosciences
28.3x-9.30%US$75.1m
ATRA Atara Biotherapeutics
0.2x-9.43%US$50.0m

Price-To-Sales vs Peers: ATRA is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (16.2x).

Price to Sales Ratio vs Industry

How does ATRA's PS Ratio compare vs other companies in the US Biotechs Industry?

148 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.8.2x17.1%
ATRA Atara Biotherapeutics
 0.2x-9.43%US$50.02m
REGN Regeneron Pharmaceuticals
3.6x5.57%US$51.55b
BIIB Biogen
2x-0.63%US$19.32b
ATRA 0.2xIndustry Avg. 8.2xNo. of Companies148PS01632486480+
148 CompaniesEstimated GrowthMarket Cap
Industry Avg.8.2x23.7%
ATRA Atara Biotherapeutics
 0.2x57.59%US$50.02m
No more companies

Price-To-Sales vs Industry: ATRA is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Biotechs industry average (7.9x).

Price to Sales Ratio vs Fair Ratio

What is ATRA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATRA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ratio0.5x

Price-To-Sales vs Fair Ratio: ATRA is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ATRA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$8.33
US$16.00
+92.08%
13.50%US$18.00US$13.00n/a3
May ’26US$7.56
US$15.33
+102.82%
20.16%US$18.00US$11.00n/a3
Apr ’26US$6.01
US$14.00
+132.95%
21.43%US$17.00US$11.00n/a2
Mar ’26US$6.91
US$13.25
+91.75%
38.62%US$18.00US$5.00n/a4
Feb ’26US$8.88
US$13.25
+49.21%
38.62%US$18.00US$5.00n/a4
Jan ’26US$13.31
US$16.50
+23.97%
24.43%US$21.00US$10.00n/a4
Dec ’25US$12.18
US$14.75
+21.15%
33.00%US$21.00US$10.00n/a4
Nov ’25US$9.71
US$150.50
+1,449.95%
92.74%US$325.00US$9.00n/a4
Oct ’25US$7.63
US$150.50
+1,872.48%
92.74%US$325.00US$9.00n/a4
Sep ’25US$7.60
US$150.50
+1,880.26%
92.74%US$325.00US$9.00n/a4
Aug ’25US$10.40
US$26.00
+150.00%
67.61%US$55.00US$11.00n/a4
Jul ’25US$8.36
US$104.38
+1,148.50%
122.93%US$325.00US$12.50n/a4
Jun ’25US$14.02
US$104.38
+644.34%
122.93%US$325.00US$12.50US$7.804
May ’25US$17.11
US$105.00
+513.59%
121.98%US$325.00US$12.50US$7.564
Apr ’25US$18.13
US$105.00
+479.31%
121.98%US$325.00US$12.50US$6.014
Mar ’25US$19.27
US$120.63
+526.05%
103.71%US$325.00US$12.50US$6.914
Feb ’25US$20.75
US$120.63
+481.33%
103.71%US$325.00US$12.50US$8.884
Jan ’25US$12.82
US$120.63
+840.91%
103.71%US$325.00US$12.50US$13.314
Dec ’24US$16.20
US$98.50
+508.21%
122.16%US$325.00US$10.00US$12.185
Nov ’24US$31.50
US$363.33
+1,053.44%
82.98%US$775.00US$35.00US$9.716
Oct ’24US$37.00
US$367.92
+894.37%
82.31%US$775.00US$35.00US$7.636
Sep ’24US$38.75
US$367.92
+849.46%
82.31%US$775.00US$35.00US$7.606
Aug ’24US$53.75
US$406.79
+656.81%
71.73%US$775.00US$50.00US$10.407
Jul ’24US$40.25
US$406.79
+910.65%
71.73%US$775.00US$50.00US$8.367
Jun ’24US$37.50
US$403.21
+975.24%
71.51%US$775.00US$50.00US$14.027
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
US$16.00
Fair Value
47.9% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/04 07:55
End of Day Share Price 2025/06/04 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atara Biotherapeutics, Inc. is covered by 16 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Yigal NochomovitzCitigroup Inc
Michael KingCitizens JMP Securities, LLC